Alnylam Pharmaceuticals (ALNY)
234.31 x 30 234.56 x 29
Post-market by (Cboe BZX)
234.56 +4.06 (+1.76%) 04/17/25 [NASDAQ]
234.31 x 30 234.56 x 29
Post-market 234.56 unch (unch) 16:00 ET
for Thu, Apr 17th, 2025
Results
download Want to compare other data? Select Fields| Symbol | ALNY | ARGX | BNTX | ||
| Company | Alnylam Pharmaceuticals | Argenx Se ADR | Biontech Se ADR | ||
| Price Information | |||||
| Exchange | NASDAQ | NASDAQ | NASDAQ | ||
| Open | 230.48 | 590.90 | 98.00 | ||
| High | 235.12 | 601.27 | 99.07 | ||
| Low | 228.96 | 590.60 | 96.54 | ||
| Last | 234.56 | 596.20 | 98.76 | ||
| Change | +4.06 | +8.61 | +0.51 | ||
| % Change | +1.76% | +1.47% | +0.52% | ||
| Volume | 601,300 | 321,800 | 723,100 | ||
| 20-Day Average Volume | 1,297,610 | 464,920 | 1,076,675 | ||
| Previous Close | 230.50 | 587.59 | 98.25 | ||
| Industry | Medical - Biomedical | Medical - Biomedical | Medical - Biomedical | ||
| Has Options | Yes | Yes | Yes | ||
| Technicals | |||||
| 20-Day Moving Average | 252.74 | 583.41 | 94.48 | ||
| 20-Day Raw Stochastic | 30.19% | 76.33% | 78.43% | ||
| 20-Day Relative Strength | 45.06% | 50.01% | 48.72% | ||
| Weighted Alpha | +16.85 | +50.62 | -6.69 | ||
| Today's Opinion | 72% Sell | 8% Sell | 72% Sell | ||
| Previous Opinion | 56% Sell | 8% Sell | 72% Sell | ||
| Last Month's Opinion | 40% Sell | 40% Buy | 24% Sell | ||
| Performance | |||||
| 5-Days | |||||
| %Chg | +3.66% since 04/10/25 | +9.15% since 04/10/25 | +6.06% since 04/10/25 | ||
| Low | 220.54 on 04/11/25 | 570.28 on 04/11/25 | 92.11 on 04/11/25 | ||
| High | 242.15 on 04/15/25 | 610.06 on 04/14/25 | 103.59 on 04/14/25 | ||
| 1-Month | |||||
| %Chg | -7.33% since 03/17/25 | -2.93% since 03/17/25 | -2.08% since 03/17/25 | ||
| Low | 205.87 on 04/09/25 | 519.70 on 04/09/25 | 81.20 on 04/07/25 | ||
| High | 300.90 on 03/24/25 | 627.01 on 03/19/25 | 103.59 on 04/14/25 | ||
| 3-Month | |||||
| %Chg | -4.75% since 01/17/25 | -6.92% since 01/17/25 | -11.77% since 01/17/25 | ||
| Low | 205.87 on 04/09/25 | 519.70 on 04/09/25 | 81.20 on 04/07/25 | ||
| High | 300.90 on 03/24/25 | 672.40 on 02/05/25 | 126.77 on 01/29/25 | ||
| 6-Month | |||||
| %Chg | -20.96% since 10/17/24 | +9.63% since 10/17/24 | -13.72% since 10/17/24 | ||
| Low | 205.87 on 04/09/25 | 519.70 on 04/09/25 | 81.20 on 04/07/25 | ||
| High | 301.05 on 10/24/24 | 678.21 on 01/14/25 | 129.27 on 01/07/25 | ||
| Key Statistics | |||||
| Market Capitalization, $K | 30,512,740 | 36,225,712 | 23,699,536 | ||
| Shares Outstanding, K | 130,085 | 60,761 | 239,971 | ||
| Annual Sales | 2,248,240,000 | 2,252,040,000 | 2,976,970,000 | ||
| Annual Net Income | -278,160,000 | 833,040,000 | -719,920,000 | ||
| Last Quarter Sales | 593,170,000 | 761,220,000 | 1,265,910,000 | ||
| Last Quarter Net Income | -83,760,000 | 774,160,000 | 274,270,000 | ||
| 60-Month Beta | 0.30 | 0.60 | 1.07 | ||
| Per-Share Information | |||||
| Most Recent Earnings | 0.06 on 02/13/25 | 1.58 on 02/27/25 | 1.15 on 03/10/25 | ||
| Latest Earnings Date | 05/01/25 | 05/08/25 | 05/05/25 | ||
| Most Recent Dividend | N/A | N/A | 3.084 on 06/02/22 | ||
| Next Ex-Dividends Date | N/A | N/A | 06/02/22 | ||
| Ratios | |||||
| Price/Earnings ttm | 0.00 | 246.89 | 0.00 | ||